


**WHAT IS CLAIMED IS:**

1. A compound of formula (I)



5

I

including enantiomers, diastereomers, tautomers,  
pharmaceutically acceptable salts and solvates thereof  
wherein:

10 A, B, D, E, X and Y are selected from N or C, J and K  
are C, and at least one of A, B, D, E, X and Y is N;

L is selected from O, NH and S, wherein L may be  
connected to any one of A, B, D, E, J, X, K or Y;

M is CH or N;

15 P is a bond or C=O, wherein P is connected to any one  
of J, X, K or Y;

Z is -(CFG)R<sup>2</sup> where F is O, H<sub>2</sub>, alkyl or substituted  
alkyl and G is O or N or none;

n is 0-4;

20 R<sup>1</sup> is selected from halogen, -CN, -CF<sub>3</sub>, substituted  
alkyl, aryl and heteroaryl;

R<sup>2</sup> is a heterocyclyl containing at least one N;

R<sup>3</sup> is selected from halogen, cyano, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein R<sup>3</sup> is connected to any one of A, B, D and E;

5 R<sup>4</sup> and R<sup>5</sup> are H;

or R<sup>4</sup> and R<sup>5</sup> may be taken together with the atoms to which they are attached to form a ring; and

R<sup>10</sup> is selected from H, alkyl, substituted alkyl, alkenyl, substituted alkenyl;

10 or E and R<sup>10</sup> may be taken together with the atoms to which they are attached to form a heteroaryl or heterocycloalkyl ring.

2. A compound of claim 1 including enantiomers,

15 diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

A is N;

B, D and E are C;

Either of X or Y or both are N;

20 L is NH;

M is N;

n is 1;

R<sup>1</sup> is selected from halogen, -CN, -CF<sub>3</sub>, substituted alkyl, aryl and heteroaryl;

25 R<sup>2</sup> is a heterocyclyl containing at least one N; and  
R<sup>10</sup> is H.

3. A compound of claim 2 including enantiomers,

diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

30 L is connected to J;

P is a bond; and


P is connected to K.

4. A compound of claim 2 including enantiomers,  
diastereomers, tautomers, pharmaceutically acceptable  
5 salts and solvates thereof wherein:


L is connected to D; and


P is connected to J.

5. A compound of claim 2 including enantiomers,  
10 diastereomers, tautomers, pharmaceutically acceptable  
salts and solvates thereof selected from:




15






;



; and



5

4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

5. A method for the treatment of CCR4-mediated conditions or diseases comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 4.
- 5
6. A method for the treatment or prevention of asthma comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 4.
- 10 7. A method for the treatment or prevention of rheumatoid arthritis comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 4.
- 15 8. A method for the treatment or prevention of psoriasis comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 4.
- 20 9. A method for the treatment or prevention of solid organ transplant rejection comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 4.
- 25 10. A method for the treatment or prevention of chronic obstructive pulmonary disease comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 4.